These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 32296913)

  • 1. Combination treatment of an IDH1 inhibitor with chemotherapy in IDH1 mutant acute myeloid leukemia.
    Gupta C; Kaulfuss S; Görlich K; Othman B; Chaturvedi A; Heuser M
    Ann Hematol; 2020 Jun; 99(6):1415-1417. PubMed ID: 32296913
    [No Abstract]   [Full Text] [Related]  

  • 2. Combination therapy with hypomethylating agents and venetoclax versus intensive induction chemotherapy in IDH1- or IDH2-mutant newly diagnosed acute myeloid leukemia-A multicenter cohort study.
    Bewersdorf JP; Shimony S; Shallis RM; Liu Y; Berton G; Schaefer EJ; Zeidan AM; Goldberg A; Stein E; Marcucci G; Bystrom RP; Lindsley RC; Chen EC; Ramos J; Stein A; Pullarkat V; Aldoss I; DeAngelo DJ; Neuberg DS; Stone RM; Garciaz S; Ball B; Stahl M
    Am J Hematol; 2024 Aug; 99(8):1640-1643. PubMed ID: 38751104
    [No Abstract]   [Full Text] [Related]  

  • 3. Evidence for Clinical Differentiation and Differentiation Syndrome in Patients With Acute Myeloid Leukemia and IDH1 Mutations Treated With the Targeted Mutant IDH1 Inhibitor, AG-120.
    Birendra KC; DiNardo CD
    Clin Lymphoma Myeloma Leuk; 2016 Aug; 16(8):460-5. PubMed ID: 27245312
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Case series of patients with acute myeloid leukemia receiving hypomethylation therapy and retrospectively found to have IDH1 or IDH2 mutations.
    Benton CB; Ravandi F; Andreeff M; Kadia T; Ruvolo V; Qiu P; Wheeler DA; Garcia-Manero G; Cortes J; Kantarjian HM; Konopleva M
    Leuk Lymphoma; 2014 Jun; 55(6):1431-4. PubMed ID: 24033106
    [No Abstract]   [Full Text] [Related]  

  • 5. Inhibition of mutant IDH1 in acute myeloid leukaemia.
    Yaqub F
    Lancet Oncol; 2015 Jan; 16(1):e9. PubMed ID: 25638561
    [No Abstract]   [Full Text] [Related]  

  • 6. IDH Inhibitors in AML-Promise and Pitfalls.
    McMurry H; Fletcher L; Traer E
    Curr Hematol Malig Rep; 2021 Apr; 16(2):207-217. PubMed ID: 33939107
    [TBL] [Abstract][Full Text] [Related]  

  • 7. IDH1 inhibitor shows promising early results.
    Cancer Discov; 2015 Jan; 5(1):4. PubMed ID: 25583779
    [TBL] [Abstract][Full Text] [Related]  

  • 8.
    Srinivasan A; Zhou Y; Scordino T; Prabhu S; Wierenga A; Simon G; Wierenga KJ; Thompson J; Shah R; Sinha AA
    Pediatr Hematol Oncol; 2020 Aug; 37(5):431-437. PubMed ID: 32166993
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SOHO State of the Art Update and Next Questions: IDH Therapeutic Targeting in AML.
    DiNardo CD; Stein EM
    Clin Lymphoma Myeloma Leuk; 2018 Dec; 18(12):769-772. PubMed ID: 30416011
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In brief: Two new drugs for AML.
    Med Lett Drugs Ther; 2018 Mar; 60(1543):e56. PubMed ID: 29635267
    [No Abstract]   [Full Text] [Related]  

  • 11. Prognostic value of IDH1 mutations identified with PCR-RFLP assay in acute myeloid leukemia patients.
    Elsayed GM; Nassar HR; Zaher A; Elnoshokaty EH; Moneer MM
    J Egypt Natl Canc Inst; 2014 Mar; 26(1):43-9. PubMed ID: 24565682
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pan-mutant-IDH1 inhibitor BAY1436032 is highly effective against human IDH1 mutant acute myeloid leukemia in vivo.
    Chaturvedi A; Herbst L; Pusch S; Klett L; Goparaju R; Stichel D; Kaulfuss S; Panknin O; Zimmermann K; Toschi L; Neuhaus R; Haegebarth A; Rehwinkel H; Hess-Stumpp H; Bauser M; Bochtler T; Struys EA; Sharma A; Bakkali A; Geffers R; Araujo-Cruz MM; Thol F; Gabdoulline R; Ganser A; Ho AD; von Deimling A; Rippe K; Heuser M; Krämer A
    Leukemia; 2017 Oct; 31(10):2020-2028. PubMed ID: 28232670
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Decitabine and venetoclax for IDH1/2-mutated acute myeloid leukemia.
    Venugopal S; Maiti A; DiNardo CD; Loghavi S; Daver NG; Kadia TM; Rausch CR; Alvarado Y; Ohanian M; Sasaki K; Short NJ; Takahashi K; Yilmaz M; Ravandi F; Kantarjian HM; Konopleva MY
    Am J Hematol; 2021 May; 96(5):E154-E157. PubMed ID: 33580980
    [No Abstract]   [Full Text] [Related]  

  • 14. Isocitrate dehydrogenase (IDH) inhibition as treatment of myeloid malignancies: Progress and future directions.
    Upadhyay VA; Brunner AM; Fathi AT
    Pharmacol Ther; 2017 Sep; 177():123-128. PubMed ID: 28315358
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New IDH1 mutant inhibitors for treatment of acute myeloid leukemia.
    Okoye-Okafor UC; Bartholdy B; Cartier J; Gao EN; Pietrak B; Rendina AR; Rominger C; Quinn C; Smallwood A; Wiggall KJ; Reif AJ; Schmidt SJ; Qi H; Zhao H; Joberty G; Faelth-Savitski M; Bantscheff M; Drewes G; Duraiswami C; Brady P; Groy A; Narayanagari SR; Antony-Debre I; Mitchell K; Wang HR; Kao YR; Christopeit M; Carvajal L; Barreyro L; Paietta E; Makishima H; Will B; Concha N; Adams ND; Schwartz B; McCabe MT; Maciejewski J; Verma A; Steidl U
    Nat Chem Biol; 2015 Nov; 11(11):878-86. PubMed ID: 26436839
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of Chemotherapy Delay on Overall Survival for AML with IDH1/2 Mutations: A Study in Adult Chinese Patients.
    Wang JH; Guo Q; Ma ZX; Ma QL; Yu MX; Yin XF; Lu SS; Xie HQ; Jiang YH; Shen D; Ma LY; Shi H; Yu WJ; Lou YJ; Li Y; Yang M; Xu GX; Mao LP; Li JH; Wang HP; Wang DM; Wei JY; Tong HY; Huang J; Jin J
    PLoS One; 2015; 10(10):e0140622. PubMed ID: 26466372
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inflammatory Cells in Atypical Eruption of Lymphocyte Recovery Carry the Same Mutations as Neoplastic Myeloid Cells.
    Prieto-Torres L; Chamizo C; Salgado RN; Atance M; Soto C; Alonso Domínguez JM; Arquero T; Piris MA; Requena L; Rodriguez-Pinilla SM
    Am J Dermatopathol; 2020 May; 42(5):360-363. PubMed ID: 31592861
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Resistance to the isocitrate dehydrogenase 1 mutant inhibitor ivosidenib can be overcome by alternative dimer-interface binding inhibitors.
    Reinbold R; Hvinden IC; Rabe P; Herold RA; Finch A; Wood J; Morgan M; Staudt M; Clifton IJ; Armstrong FA; McCullagh JSO; Redmond J; Bardella C; Abboud MI; Schofield CJ
    Nat Commun; 2022 Aug; 13(1):4785. PubMed ID: 35970853
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IDH1/2 Mutations in Cancer Stem Cells and Their Implications for Differentiation Therapy.
    Molenaar RJ; Wilmink JW
    J Histochem Cytochem; 2022 Jan; 70(1):83-97. PubMed ID: 34967233
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FDA Approval Summary: Ivosidenib for Relapsed or Refractory Acute Myeloid Leukemia with an Isocitrate Dehydrogenase-1 Mutation.
    Norsworthy KJ; Luo L; Hsu V; Gudi R; Dorff SE; Przepiorka D; Deisseroth A; Shen YL; Sheth CM; Charlab R; Williams GM; Goldberg KB; Farrell AT; Pazdur R
    Clin Cancer Res; 2019 Jun; 25(11):3205-3209. PubMed ID: 30692099
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.